Tiverton Asset Management LLC grew its position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 4.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,437 shares of the medical equipment provider’s stock after purchasing an additional 227 shares during the period. Tiverton Asset Management LLC’s holdings in Zimmer Biomet were worth $640,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of ZBH. Dimensional Fund Advisors LP raised its holdings in shares of Zimmer Biomet by 7.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,076,723 shares of the medical equipment provider’s stock worth $111,669,000 after acquiring an additional 77,026 shares during the period. Geode Capital Management LLC grew its holdings in shares of Zimmer Biomet by 8.4% in the fourth quarter. Geode Capital Management LLC now owns 2,641,717 shares of the medical equipment provider’s stock valued at $273,516,000 after purchasing an additional 205,532 shares during the period. Quantamental Technologies LLC acquired a new stake in Zimmer Biomet during the first quarter worth about $69,000. Janus Henderson Group PLC raised its stake in Zimmer Biomet by 34.6% during the first quarter. Janus Henderson Group PLC now owns 72,118 shares of the medical equipment provider’s stock worth $9,210,000 after purchasing an additional 18,553 shares during the period. Finally, United Bank raised its stake in Zimmer Biomet by 9.9% during the first quarter. United Bank now owns 11,003 shares of the medical equipment provider’s stock worth $1,405,000 after purchasing an additional 988 shares during the period. Institutional investors own 89.39% of the company’s stock.
Shares of Zimmer Biomet stock traded down $1.29 during trading on Tuesday, hitting $135.79. 40,128 shares of the stock were exchanged, compared to its average volume of 904,650. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.19 and a quick ratio of 0.56. The firm’s 50-day moving average price is $135.99 and its 200 day moving average price is $125.19. The stock has a market cap of $28.69 billion, a price-to-earnings ratio of 17.77, a price-to-earnings-growth ratio of 2.50 and a beta of 1.15. Zimmer Biomet Holdings Inc has a 12-month low of $96.99 and a 12-month high of $140.71.
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.71%. The ex-dividend date of this dividend is Friday, September 27th. Zimmer Biomet’s dividend payout ratio (DPR) is 12.57%.
In related news, VP Chad F. Phipps sold 7,000 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $138.28, for a total value of $967,960.00. Following the completion of the sale, the vice president now directly owns 37,722 shares of the company’s stock, valued at $5,216,198.16. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 39,947 shares of company stock worth $5,580,349 over the last quarter. 0.72% of the stock is owned by company insiders.
Several research firms have recently weighed in on ZBH. Zacks Investment Research raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $149.00 price target for the company in a research note on Saturday, August 31st. Raymond James lifted their target price on Zimmer Biomet from $145.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. Cowen set a $140.00 price target on Zimmer Biomet and gave the company a “hold” rating in a research note on Friday, July 26th. Citigroup increased their price target on Zimmer Biomet from $146.00 to $158.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, Jefferies Financial Group raised their price objective on Zimmer Biomet from $150.00 to $167.00 and gave the stock a “buy” rating in a research report on Monday, July 29th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet has a consensus rating of “Buy” and an average price target of $142.26.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Further Reading: Why do companies engage in swaps?
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.